top of page

Pick the Winners Study

This study aims to characterize CD19-specific CAR-T cells that successfully achieve immune memory and long-term persistence in children and young adults with B-ALL.

ADDITIONAL ELIGIBILITY

  1. treated with commercial CAR T cells


  2. patients with B cell aplasia (defined as B cells <1%), sustained for ≥6 months


  3. received no additional interventions beyond CD-19 CAR T-cell therapy

COLLECTION

single peripheral blood sample (10mL EDTA and 10mL NaHep)

  • If patient reaches upper limit of blood volume collection, can reduce NaHep collection to 5mL

REQUIREMENTS

Foresight ICF signed

bottom of page